Guys - my senility is playing up. Recently (last few days/weeks) someone dissected their favourite biotech play comparing pipeline assets to others. I think it was here or maybe NPI.
Anyone got any recollections/pointers?
I think it mentioned NKTR but can’t recall if that was the play or one of the comparisons. I thought it talked about potential vs Car-T and even CRISPR tech plays.
Am I losing my mind?
Thank in advance
Hi Ant, I think the post you are looking for is by HeartMD, post number 38040. If it is not, that post is still worth reading, very well thought out.
Yeh I’ve been looking at that and I enjoyed it. My senility is so bad I can’t remember if that was the one I was thinking of.
I want to say yes but I’m pretty sure the post I was talking about compare companies and drug discovery technologies as well as reviewed assets in trial.